Goldman Sachs analyst Salveen Richter has upgraded Taysha Gene Therapies (TSHA) to a Buy rating, setting a price target of $11. This positive outlook is primarily driven by optimism regarding the company's progress in treating Rett syndrome. The analyst is confident that Taysha can achieve the crucial 33% response rate in the REVEAL study, which is necessary to meet the success criteria for this clinical trial. This development signifies a promising future for the company's therapeutic initiatives.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.